During the 1990s, MSF teams made a bitter observation: we were failing to treat some of our patients suffering from infectious diseases, while in developed countries, remarkable progress was being made in the field of health. Two decades on, medicines in developing countries are still either too expensive, aren't suitable to be used in many of the contexts in which we work (for example, in hot, humid conditions or where there's a lack of electricity), or simply don't exist for the diseases we need to treat.
In 1999, we launched the Campaign for Access to Essential Medicines, now known as the Access Campaign. Its mission focuses on three areas: overcoming barriers to access to essential medicines, stimulating research and development for neglected diseases, promoting health exceptions to global trade agreements.
In 2003, MSF joined several research institutes, including the Institut Pasteur, to create the Drugs for Neglected Diseases initiative (DNDi), a non-profit research and development organisation engaged in research and development of new treatments for neglected diseases.

MSF strengthening commitment to access to products for healthcare

Syrians suffer from more funding cuts despite severe medical needs

MSF reveals cost of landmark TB clinical trial in push for drug-development cost transparency

Urgent measures needed to address gaps in Universal Health Coverage targets

Universal Health Coverage targets leave behind the most vulnerable

Johnson & Johnson and Cepheid must pledge access to lifesaving TB medicines and tests

MSF statement on WHO negotiating body meeting on pandemic prevention, preparedness and response

Lack of a real IP waiver on COVID-19 tools is a disappointing failure for people
